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The immune system is functionally diverse, able to make 
a refined response to hundreds of different types of 
infectious organisms. The initiation of an immune 
response to an infection requires collaboration between 
innate immune cells, which recognize general distin­
guishing features of pathogens, and the T lymphocytes of 
the adaptive immune system, whose highly variable 
antigen receptors are specific for a given pathogen. The 
activation of T lymphocytes depends on interactions 
with professional antigen­presenting cells (APCs), 
specialized cells of the innate immune system that are 
directly activated by the pathogens they engulf and 
regurgitate for presentation to, and activation of, T cells. 
The T cells then proliferate and are mobilized to protect 
the body by activating other immune cells or by killing 
infected cells. Among the immune cells activated by T 
lymphocytes, most importantly, are the B lymphocytes 
that produce antibodies. T lymphocytes direct the types 
of antibodies that B cells produce and the activity of other 
immune cells, thereby directing the immune response to 
optimally provide protection against different types of 
infections.
At the end of an immune response, the majority of 
activated B and T cells will undergo apoptosis, but a small 
number remain as memory cells, primed ready in case 
the host is exposed to the same infection [1,2]. Vaccines 
must work in a similar way, priming antigen­specific 
T and B cells, some of which convert to the memory cells 
that will control subsequent infections by the invader 
targeted by the vaccine. Moreover, like the infection itself, 
the vaccine must generate the optimal type of immune 
response to protect against a particular pathogen.
The different ways in which the immune system can 
respond to antigen are schematically summarized in 
Figure 1, which shows the two major classes of 
T  lymphocyte, cytotoxic (or CD8) cells and helper (or 
CD4) cells, and their principal actions. For example, virus 
infections can be cleared by cytotoxic T cells (CTLs) or 
antibodies, whereas intracellular bacteria and parasites 
are most effectively controlled by T cells that produce 
cytokines specialized to activate particular groups of 
innate immune cells (Figure 1) [3­5].
The immune system is thought to distinguish the 
different kinds of pathogens through recognition by 
innate immune cells of pathogen­associated molecular 
patterns (PAMPs) on microorganisms, which enables 
responding cells to direct the adaptive responses along 
the pathway that will best help to reject the invader. 
PAMPs include, for example, characteristic cell wall 
components of bacteria, double­stranded RNA, which is 
found in some viruses, and CpG­rich DNA, which can be 
present in bacteria and viruses. These microbial compo­
nents are detected by innate signaling pattern recognition 
receptors (PRRs), among the best known and most 
versatile of which are the Toll­like receptors (TLRs). 
Different members of the TLR family of membrane­
bound receptors are specialized for detection of different 
classes of pathogens. In addition, many cytoplasmic 
proteins have recently been recognized to be important 
in innate immunity as PRRs [6­9]. Recognition of PAMPs 
by responding cells promotes recruitment of innate 
immune cells and APCs and activates APCs, increasing 
uptake of antigen and inducing cell­surface molecules 
and soluble mediators that are required for T cell 
activation. Together, these effects influence the 
magnitude of T and B cell responses and the numbers of 
memory cells that are produced. Not only do they serve 
to warn and activate the cells of the adaptive immune 
response but, impor tantly, they also control the type of 
immune response that follows.
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effective. Research on protective immunity and 
adjuvants that generate vigorous immune responses 
may help generate effective vaccines against such 
pathogens.
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Currently, three main types of vaccine are used in 
humans: live attenuated vaccines composed of a virus or 
bacterium that is similar to but less pathogenic than the 
real pathogen; inactivated vaccines that are heat­
inactivated or chemically inactivated particles of the 
pathogen; or subunit vaccines that are made from 
components of the pathogen. Vaccines contain not only 
the antigen that is the target of the adaptive immune 
response, but either PAMPs or other substances that 
amplify or influence the adaptive response: these are 
known as adjuvants. In the live attenuated vaccines, the 
antigens that are recognized by the cells of the adaptive 
immune system are coupled to the PAMPs that activate 
professional APCs, just as they are in the pathogen itself, 
and these thus provide a natural adjuvant. Subunit 
vaccines, by contrast, consist of the purified antigens that 
are specifically recognized by lymphocytes, and although 
they are safer than whole­organism vaccines, they are 
unable, on their own, to activate the immune system 
optimally because they lack intrinsic PAMPs. Such 
vaccines require the addition of adjuvants that enhance 
their immunogenicity and influence the magnitude and 
nature of the response.
Adjuvants may promote immune responses by 
recruiting professional APCs to the vaccination site, by 
increasing the delivery of antigens to APCs, or by 
activating APCs to produce cytokines and provide 
activating signals to T cells. One adjuvant that has a long 
historical use in human vaccines is aluminum salt 
(sometimes referred to as alum). Proteins from the 
pathogen are adsorbed onto the aluminum salt, creating 
a suspension that is injected intramuscularly. Despite its 
long­standing and widespread use in human vaccines, it 
is still not clear exactly how this adjuvant works. 
Although it was widely believed that aluminum adjuvants 
promote their effects by maintaining a slow­releasing 
depot of antigen to the immune system, it is now clear 
that they promote multiple effects on the innate immune 
system. In addition, excision of aluminum adjuvant 
nodules after immunization has no impact on the 
magnitude of the immune response, which has brought 
the role of the depot into question [10].
Adjuvants were first deliberately introduced into 
vaccines after it was shown that aluminum salts and 
other particles could enhance immune responses [11]. At 
present, there are very few licensed vaccine adjuvants for 
clinical use. In the USA, aluminum salts have been, for 
many years, the only adjuvants that could be added to 
human vaccines. Recently, monophosphoryl lipid A 
(MPL), a derivative of the highly immunogenic bacterial 
cell wall component lipopolysaccharide (LPS), has been 
approved for use in the GlaxoSmithKline vaccine for 
Figure 1. Activation and differentiation of T lymphocytes. Dendritic cells (DCs) take up antigen delivered either by an infectious pathogen or 
by a vaccine (stage 1). DCs are activated by conserved components of pathogens binding to pattern recognition receptors (PRRs) that induce the 
expression of co-stimulatory molecules and the release of inflammatory cytokines. Vaccines that do not contain intrinsic adjuvants are delivered 
with added adjuvants, such as aluminum salts, that also activate inflammatory pathways. DCs degrade the antigen into peptides that are returned 
to the cell surface on MHC molecules and presented to CD8 and CD4+ T cells - antigen being presented to CD8+ T cells by MHC class I molecules, 
and to CD4+ T cells on MHC class II molecules (stage 2). T cells also require signals provided by the co-stimulatory molecules and inflammatory 
cytokines to be fully activated. Activation results in cell proliferation (stage 3) and effector cell differentiation (stage 4). CD4+ T cells can make 
cytokines that activate innate immune cells (such as macrophages and neutrophils) to kill pathogens. Activated CD4+ T cells can also provide help 
to B cells, expressing the cell-surface and soluble mediators required for the production of high-affinity class switched antibody. Effector CD8+ T 
cells can kill infected cells by releasing cytotoxic granules or can activate other cell types by the release of inflammatory cytokines.
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human papillomavirus in combination with aluminum 
hydroxide. In Europe several additional adjuvants are 
used, including the oil­in­water adjuvants MF59 and 
ASO3, made by Novartis and GlaxoSmithKline, 
respectively (Table 1). As well as these, a large number of 
novel vaccine adjuvants have been studied in the 
laboratory, and some of them have also been used in 
clinical trials in humans (Tables 1 and 2). Whether these 
adjuvants will pass the two major criteria required for 
general use (effectiveness and safety) remains to be 
determined.
Adjuvants and antibody production
Most current vaccines act by inducing long­lived plasma 
cells ­ terminally differentiated B cells ­ that continuously 
secrete antibody over a considerable period of time [5]. 
Antibodies act quickly by binding to and thus stopping 
the pathogen, or products of the pathogen, in their tracks 
before damage to the host occurs. They are thus ideal for 
control of many diseases, including infection by viruses 
and intoxication by a number of bacterial products, 
including tetanus and diphtheria toxins [5]. Many of the 
viral vaccines use attenuated viruses as agents and 
generate good, long­lasting antibody production [12]. 
However, this is not so true for the subunit vaccines. For 
example, the tetanus vaccine, which is composed of a 
toxoid (an inactivated toxin that retains its antigenic 
properties) adsorbed to aluminum adjuvant, leads to the 
generation of plasma cells that make anti­tetanus­toxin 
antibody. However, this vaccine is routinely given to 
individuals every 10 to 15 years as the specific plasma 
cells making the antibody eventually die off [13]. This is 
in contrast to the plasma cells that are generated 
following infection with live measles virus. These plasma 
cells are predicted to have a half­life of 3,014 years [12]. 
How the infection manages this and, therefore, how an 
adjuvant could achieve this are still unclear.
Table 1. Adjuvants in use or being tested for use in human vaccines
Adjuvant Composition Current status References
Aluminum  Aluminum hydroxide or aluminum phosphate In use in vaccines against DT, DPT, HBV, Hib, Streptococcus pneumoniae,  [94]
salts (alum) non-crystalline gels meningococcal and HPV infections
MF59 Oil (squalene)-in-water emulsion In use in influenza vaccine (Europe); in trials for malarial, hepatitis C  [18,95-99] 
  and HIV vaccine systems
MPL Non-toxic derivative of LPS  Used in various trials in combination with oil (squalene)-in-water  [87,100] 
  emulsions for malaria and leishmaniasis or in liposomal formulation
QS21 Purified fraction of Quil A  Trialed alone and in combination with MPL (AS02, AS01) for malaria,  [87] 
  influenza and cancers
ISCOMS Liposomes containing QS21 Trials for influenza vaccines [101,102]
AS01 Liposomal formulation containing MPL and QS21 Trials for malaria vaccines (a more effective formulation than AS03 and AS04)  [87]
AS02 Oil (squalene)-in-water emulsion of MPL and QS21 Trials for malaria, HBV and TB vaccines [103]
AS03 Oil (squalene)-in-water emulsion Trials for influenza vaccines [20,21]
AS04 Aluminum hydroxide and MPL Trials for HBV and HPV vaccines [104,105]
MPL-SE MPL in a oil (squalene)-in-water emulsion Trials for leishmaniasis vaccines [100]
Abbreviations: DPT, Diphtheria pertussis tetanus toxoid; DT, Diphtheria toxoid; HBV, Hepatitis B virus; Hib, Haemophilus influenzae , HIV, human immunodeficiency virus; 
HPV, human papilloma virus; ISCOMs, immune stimulating complexes; LPS, lipopolysaccharide; MPL, monophosphoryl lipid A; TB, tuberculosis.
Table 2. Proposed mechanisms of adjuvant activity of major adjuvant components
Adjuvant Composition Adjuvant activity Mechanism of adjuvant action References
Aluminum AlOH or AlPO4 non-crystalline gels Antibody and TH2 cells ↑ Chemokine/cytokine production; ↑ recruitment of [31,34, 46,
salts   monocytes and differentiation to DC; ↑ antigen uptake  106,107]
   by DC
MF59 Oil (squalene)-in-water emulsion ↑ Ab titre; ↑ Ab cross-reactivity;  ↑ Chemokine/cytokine production; recruitment of [34,
  drives TH2 cells myeloid DCs to injection site; ↑ antigen uptake by DCs 108-110]
TLR ligands MPL, GpG, imiquimod, resiquimod  Drives TH1 and CTL cells;  TLR signaling in DCs promotes antigen presentation [111]
 (both imidazoquinolinamines) or  ↑ T cell memory on MHC I and MHC II, enhanced migration of DCs to 
 poly(I:C)   lymph nodes and DCs cytokine production; may have  
   direct impacts on lymphocytes
QS21 Purified fraction of Quil A that  Antibody, TH1 and CTL Enhances protective responses through poorly [97]
 has lower toxicity and retains  responses understood mechanisms; has lytic capacity and local  
 adjuvant effects   reactogenicity 
Abbreviations: Ab, antibody; CTL, cytotoxic T lymphocyte; MPL, monophosphoryl lipid A; poly(I:C), a synthetic analog of double-stranded RNA; Th, T helper cell; TLR, 
Toll-like receptor.
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The type of antibody produced is also affected by the 
adjuvant. There are five major classes of antibody with 
different properties and, ideally, vaccines should be 
designed to induce the antibody class that would be most 
effective in dealing with the pathogen. Immunoglobulin A 
(IgA) is highly effective against agents that infect through 
mucosal surfaces (see, for example, [14]). This factor may 
be responsible for the overall greater effectiveness of the 
Sabin (live attenuated) than the Salk (heat killed) polio 
vaccine. This is because the oral, live vaccine induces IgA 
secretion in the gut and respiratory tract, whereas the 
inactivated intramuscular Salk vaccine does not [15]. It is 
possible that adjuvants can be selected to enhance 
secretory IgA production, probably through their effects 
on APCs and T cell differentiation (see below).
Antibodies are sometimes not enough
Influenza vaccines operate by inducing antibodies against 
the two main surface proteins from the virus, hemag­
glutinin and neuraminidase. In so doing they effectively 
protect against infection by influenza strains expressing 
versions of these proteins present in the vaccine. 
However, these two proteins change as a consequence of 
mutation and re­assortment and the vaccine must be 
reformulated each year to contain the hemagglutinin and 
neuraminidase of the expected strain. Moreover, the 
vaccine has historically been, and in the US is currently, 
administered in the absence of an adjuvant. This means 
that larger doses must be given and immunity has been 
difficult to induce against the proteins found in emerging 
strains, such as those in H5N1 viruses that cause avian flu 
[16]. This may be partly because individuals have memory 
cells that can recognize annual but not emerging strains 
of the virus. Memory cells can respond in the absence of 
high levels of co­stimulation [17] (Figure  1) and, there­
fore, can be activated in the absence of an adjuvant. A 
primary response is required, however, to protect against 
newly emerging virus strains as they are more anti­
genically distinct from annual influenza strains. This 
primary response cannot be activated in the absence of 
the inflammation induced by added adjuvant.
Addition of adjuvants (MF59, ASO3 or aluminum salts; 
Table  1) to influenza vaccines increases antibody titers 
and persistence [18­21]. However, these approaches do 
not provide cross­reactivity to distinct subtypes of the 
virus. The same is true for the attenuated influenza 
vaccine Flu­Mist, which is also modified each year, 
although this vaccine may activate cross­reactive CD8+ T 
cells, at least in children [22]. CD8+ T cells recognize less 
variable parts of the virus ­ for example, in the core 
proteins [23­30] ­ and may provide a more cross­reactive 
response that could be induced by new vaccines.
Besides influenza there are clearly many other 
infections, HIV and malaria, for example, for which 
antibodies are not at all, or are insufficiently, protective. 
In these cases, both humoral immunity, mediated by 
antibodies, and cell­mediated immunity, which depends 
on cytotoxic T cells or T cells that activate immune cells 
by means of cytokines, may be required for effective 
protection.
Contribution of adjuvants to T cell priming
Dendritic cells (DCs) are key antigen­presenting cells in 
the initiation of T cell responses, and are thus likely to be 
a major target of adjuvant effects. In the absence of 
infection, DCs are distributed throughout the tissues as 
phagocytic cells. The presence of infection is signaled to 
these cells both directly, by pattern­recognition receptors 
(PRRs) for microbial constituents, and indirectly, by 
inflammatory cytokines released by other innate immune 
cells that recognize microbial constituents. These signals 
activate the DCs to undergo a process known as matura­
tion and to migrate into secondary lymphoid organs 
where they activate naïve T cells. DC maturation involves 
increased processing of microbial proteins, portions of 
which are presented to T cells on major histocompatibility 
complex (MHC) molecules (discussed below). This serves 
as a required first activation signal. In addition, activation 
of DCs by PRRs results in expression on the surface of 
the DCs of so­called accessory and co­stimulatory 
molecules and the secretion of cytokines. Co­stimulatory 
signals are secondary signals required for DCs to activate 
naïve T cells, and cytokines offer a third signal to direct 
their differentiation along different pathways (Figure 1, 
stage 2). One way in which adjuvants such as aluminum 
salts and MF59 act is by promoting inflammation and 
infiltration of DCs into the site of inoculation and 
improving the uptake of associated antigens by DCs 
[31­34].
Adjuvant effects are relatively well understood for signals 
that induce T helper cell 1 (TH1) responses, which are 
characterized by T helper cells that produce high levels of 
IFNγ, and other cytokines that activate antimicrobial 
effects at the effector site. These TH1 driving signals are 
known to operate through TLRs to induce secretion of 
interleukin (IL)­12, which drives differentiation of TH1 
cells [35­38]. Adjuvants such as QS21 or other saponins 
drive TH1 responses and are thought to work by the 
induction of IL­12 in DCs [39]. Aluminum salts, however, 
do not directly induce signaling through TLRs and do not 
stimulate IL­12 production by DCs. Instead, aluminum 
adjuvants drive TH2 responses [40], by mechanisms that 
are much less well understood.
The requirements for antigen presentation to CD8+ 
T  cells, which give rise to cytotoxic cells, are distinct 
from those for the CD4 helper T cells. CD8+ T cells are 
specialized for detection of agents, such as viruses, that 
invade the cytoplasm, and the pathway by which antigen 
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reaches the surface from the cytoplasm is distinct from 
the pathway followed by internalized antigen. Briefly, all 
antigens are carried to the cell surface by molecules 
encoded in the MHC. Internalized antigen is carried to 
the cell surface by one class of MHC molecules, MHC 
class II, which promotes activation of CD4 cells. In 
contrast, endogenous antigen reaches the cell surface on 
a different class, MHC class I, which activates CD8 cells. 
To activate cytotoxic T cells, antigen internalized by DCs 
must cross to the MHC class I pathway before 
reappearing on the cell surface, a process known as cross­
presentation, for which specific subsets of DCs are 
specialized [41]. Adjuvant systems are likely to have 
important effects on antigen cross­presentation. For 
example, some TLR ligands, such as LPS, can promote 
delivery of essential parts of the MHC class I antigen­
processing pathway to vesicles of the internalization 
pathway, presumably enhancing cross­presentation [42]. 
Other adjuvants, such as immunostimulatory complexes 
(ISCOM/ISCOMATRIX), particulate adjuvants made up 
of lipids, cholesterol and the saponin adjuvant Quil A, 
may promote cross­presentation and activation of CD8 
cells by partly bypassing the normal antigen­processing 
pathway [43].
The role of adjuvant­induced inflammation in enhanc­
ing the initiation of T cell responses is an unresolved 
issue. For example, a crucial complex in the inflammatory 
pathway, the inflammasome, is suggested in some studies 
[44,45], but not in others [46­48], to be required for 
recruitment of APCs and enhanced T and B cell 
responses following immunization with aluminum salt 
adjuvants, despite the use of similar methods in 
genetically identical mice. It is also not clear whether 
PRR­mediated pathways must be activated in DCs 
themselves, or whether inflammatory responses in local 
tissue cells can account for some adjuvant effects [49]. 
For example, inflammatory cytokines can recruit to the 
injection site monocytes that differentiate into DCs. 
These may subsequently be activated to migrate into the 
lymph node to present antigen to T cells. Such 
recruitment is one action of the MF59 adjuvant, an 
emulsion of oil (squalene) in water, and aluminum salt 
adjuvants [31,34].
Establishment of T cell memory
Despite many years of research, immunologists still have 
little idea of which signals are required for the generation 
of memory T cells. This may be a stochastic process, in 
which a percentage of cells are randomly selected to 
survive, or a selective process, in which a subset of cells is 
designated early in the response to survive and generate 
the memory pool. Memory cells can be identified by 
characteristic markers [50­52] that may be useful in 
measur ing the effectiveness of different antigen­adjuvant 
combinations. In some cases, the generation of memory 
cells that express lymphoid homing markers is associated 
with long­term survival and thus protection [53]. In 
contrast, other investigators argue that memory T cells that 
migrate into non­lymphoid organs, where re­infec tions are 
likely to occur, provide the most effective protection [54]. 
Therefore, measurements of protective capacity (for 
example, reduced viral titers or bacterial loads following 
challenge) are more useful indicators of a successful vaccine 
than the phenotype of the memory cells.
Many variables can affect the number and phenotype 
of memory cells. For example, a large dose of antigen can 
activate a larger number of cells, but a low dose may be 
preferable in a vaccine, if it activates only cells with high­
affinity receptors, which may be more effective in some 
infections [55,56]. This seems to be true in mouse models 
of Mycobacterium tuberculosis in which low­dose priming 
induces highly sensitive T cells that can make a broad 
cytokine response that is associated with protection [55].
Likewise, the amount of inflammation, which in the 
case of a vaccine can be influenced by the addition of an 
adjuvant, affects the phenotype and number of the 
memory cells generated, partly because inflammatory 
signals are required for the efficient expansion and 
survival of T cells [57]. The speed with which memory 
cells are generated, however, can be increased by 
reducing inflammation during priming, resulting in the 
more rapid generation of memory cells [58,59]. It may be 
critical, therefore, to adjust the amount of antigen and 
adjuvant depending on how many and what type of 
memory cells are required to provide protection. This 
leads us to the question of how important the two major 
classes of T cells ­ CD4 cells and CD8 cells ­ are in 
providing protection.
CD4 T cell-mediated protection
It is clear that CD4+ T cells are critical directors of both 
cellular and humoral memory. It has been established for 
many years that CD4+ T cells provide help to B cells [60], 
but CD4+ T cells are also crucial for the generation of 
effective CD8 memory T cells [61]. Any vaccine, regardless 
of its intended action, must therefore activate helper CD4+ 
T cells. Perhaps the most important considera tion for 
deciding what adjuvant to use in a vaccine is what type of 
CD4+ T cell response is required to direct the ensuing 
ideal immune response. At least five subsets of CD4+ 
T  helper are now recognized: TH1 and TH2 cells, which 
activate macrophages in distinct ways and induce 
production of different classes of antibodies in B cells; 
TH17 cells, which are inflammatory; T follicular cells, 
which are specialized for activating B cells; and regulatory 
T cells, which are thought to prevent autoimmunity 
(Figure 2). These subsets have been reviewed extensively 
elsewhere [62,63]; here we will mainly discuss TH1 cells as 
McKee et al. BMC Biology 2010, 8:37 
http://www.biomedcentral.com/1741-7007/8/37
Page 5 of 10
these have been most associated with protection following 
vaccination.
Although it is clear that CD4+ T cells must be activated 
following vaccination, the importance of generating CD4 
memory cells is less obvious. We have recently discussed 
the subject in some detail [64] and so will not go into 
specifics here, but a careful analysis of the available 
evidence suggests that relatively few protective immune 
responses depend on CD4+ T cell memory. Protection 
from M. tuberculosis is, however, a good example of how 
CD4 memory cells can act. CD4+ T cells producing the 
important cytokine interferon (IFN)γ provide protection 
to M. tuberculosis by activating macrophages in infected 
lungs [4]. The current M. tuberculosis vaccine, Bacille 
Calmette­Guérin (BCG), protects young children from 
the worse forms of the disease [65,66], but it is of limited 
use in adults [4]. Therefore, much M. tuberculosis vaccine 
research is focused on a prime­boost approach, a series 
of two vaccines, with BCG as the primary vaccine and a 
second experimental vaccine designed to re­activate and 
increase the protective memory response. As the boost 
several substances have been tried. For example, a 
modified vaccinia virus (MVA) that expresses a protein 
from M. tuberculosis, 85A, has been tested in animals 
and humans. By using a vaccinia vector, a broad immune 
response, including IL­12 production by DCs and IFNγ 
production by CD4 cells, is induced [67,68]. In mouse 
studies, boosting with MVA85A resulted in reduced 
levels of bacteria in challenged animals [69,70]. The 
vaccine also successfully boosts antigen­specific cells in 
humans and the consequent memory cells produce a 
range of cytokines, including IFNγ and tumor necrosis 
factor (TNF)α [71­73]. Such multifunctional cells, which 
also make cytokines at higher levels, have been shown to 
provide protection against infections, including 
M. tuberculosis, in mouse models [55,73,74].
CD8 T cell-mediated protection
Although it has been difficult to demonstrate direct protec­
tive effects of CD4 memory T cells, the differen tiation of 
CD8+ T cells into CTLs has long been a measure of their 
protective efficacy (Figure 1). Following activation and 
clonal expansion in lymphoid organs, CTLs migrate to sites 
of inflammation, where they kill infected cells by inducing 
apoptosis, thus limiting and eventually clearing the 
infection. CTLs have been shown to provide protection in 
various mouse infection models [3,75­78], and CTL activity 
has been demonstrated in assays in vitro using human 
Figure 2. CD4+ T helper subsets. CD4+ T cells can differentiate into different subsets depending on the cytokine milieu present during T cell 
activation. TH1 cells, activated in the presence of IL-12 and IL-18 produced by activated DCs, make IFNγ, which is important in activating macrophages 
to kill intracellular bacteria, such as M. tuberculosis. IL-4 made by TH2 cells activates macrophages to expel parasites (the cellular source of the IL-4 that 
promotes TH2 development is currently poorly defined). T follicular (Tfh) cells can make the canonical cytokines that TH1 or TH2 cells produce, but 
they also make IL-21 and express cell-surface molecules, such as CD40 ligand and inducible T cell co-simulator (ICOS), that are required for effective B 
cell responses and production of high-affinity, class-switched antibodies. The more recently described TH17 cells can produce IL-17 and IL-22 and are 
generated in the presence of IL-6 and TGFβ. IL-17 and IL-22 are important for promoting the influx of neutrophils to inflamed sites and the production 
of antimicrobial peptides, respectively. TH17 cells are thought to be important in defense against extracellular bacteria and fungi. Activated T cells can 
also differentiate into regulatory T cells (Tregs) in the presence of TGFβ and/or retinoic acid (RA). These cells can inhibit and control immune responses 
to prevent excessive inflammation through cell-surface molecules (such as CTLA-4) or cytokines, such as IL-10.
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CD8+ T cells [23,79,80]. CTLs are also correlated with 
protection in humans infected with influenza [79,81,82].
There has been a shift in the focus of influenza vaccine 
development towards generating memory CD8+ T cells 
that may be able to provide more cross­reactive 
protection; this is because, as mentioned above, the 
antigens that CD8+ T cells recognize are found in less 
variable portions of the virus [23­30]. Several approaches 
have been developed, and perhaps the most interesting 
are those that target the lung, generating memory cells in 
the correct location to provide the most rapid protection. 
For example, peptides recognized by CD8+ T cells have 
been combined with a lipid moiety, Pam­2­Cys, that 
activates a TLR on DCs to successfully prime protective 
CD8+ T cells [83]. When delivered intranasally, this 
vaccine generates CD8+ T cells that migrate to the lung 
to provide immediate protection.
The use of peptide fragments rather than whole 
antigens is a limitation for the outbred human population 
because different fragments are recognized by the T cells 
of different individuals, and a very large number of 
different fragments would need to be identified and 
included. As an alternative, whole detergent­inactivated 
influenza virus can be combined with ISCOMs, which 
can deliver enclosed antigen directly to DCs and activate 
a range of innate cells, generating a TH1 and CTL 
response [84]. ISCOMs containing inactivated influenza 
virus have been used to generate an intranasal vaccine 
that includes all the viral proteins and can induce cross­
reactive protection [85]. This protection required both 
CTL and antibodies, indicating that the ISCOM vaccine 
induced an effective cell­mediated and humoral response.
The killing of infected cells by CTLs and TH1 cells is an 
effective way to clear an infection with an intracellular 
pathogen. However, in some cases, such as infection of 
the liver by the hepatitis B virus, IFNγ­producing CD8+ 
T cells offer more effective protection because the virus 
can be cleared without the death of a large number of 
host cells [86]. In a similar vein, IFNγ­producing CD8+ 
T  cells are associated with protection in individuals 
vaccinated with the RTS,S malaria vaccine. This vaccine 
contains a protein from the parasite fused to a surface 
protein from the hepatitis B virus [87]. Although not 
enough is known about the mechanisms by which 
immune individuals resist infection, it is believed that 
both humoral and cell­mediated immunity directed 
against multiple antigens expressed at different stages of 
the parasite’s lifecycle are required for protection during 
malarial infection [88]. The adjuvant system used in the 
most successful malarial vaccine is AS02, a preparation 
that contains both a saponin component and the TLR 
agonist MPL formulated in a particulate system. Notably, 
both saponin and MPL were required to induce a modest 
level of protection in immunized individuals [89]. In 
contrast, vaccines using the same antigen with aluminum 
hydroxide and MPL (AS04) or in an oil­in­water 
emulsion (AS03) induced high levels of antibody but 
failed to protect against infection. A greater 
understanding of the responses in protected individuals 
may help to efficiently identify more effective antigen­
adjuvant combinations. For example, the successful 
adjuvant, AS02, promotes CD8 responses, TH1 
differentiation and broad antibody responses [90]. This 
suggests that both antibody­ and cell­mediated immunity 
have important roles in defense against this complex 
pathogen.
In pursuit of the ideal adjuvant
The immune system has a diverse range of mechanisms 
at its disposal to deal with infectious organisms (Figures 1 
and 2). Successful vaccines should aim to activate several 
of these, creating a redundant protective response that 
can cope with mutations and pathogen escape strategies. 
Although live attenuated viral and bacterial vaccines can 
activate all arms of the immune system [67,91,92], 
adjuvants have so far not reached this goal. By combining 
adjuvants, such as aluminum salts with MPL, or using 
prime­boost strategies using DNA and then viral or 
bacterial vectors, both humoral and cell­mediated 
responses can be activated, and some successes, as 
discussed above, have been reported. Yellow fever and 
smallpox (vaccinia) viruses are highly effective live 
vaccines that promote B and T cell memory and promote 
lifelong protection [91,93]. Recent work from the groups 
of Rafi Ahmed and Bali Pulendran into why the yellow 
fever and vaccinia vaccines work so well may provide 
markers of both innate activation and early adaptive 
responses, providing biomarkers to evaluate the success 
of new vaccine and adjuvant strategies [91,92].
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